Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sepracor raises $400 million

SEPR sold $400 in convertible subordinated debentures, with a $60 million overallotment option. The debentures bear 5 percent interest,

Read the full 195 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE